Login / Signup

A Wall Fragment of Cutibacterium acnes Preserves Junctional Integrity Altered by Staphylococcus aureus in an Ex Vivo Porcine Skin Model.

Irene MagnificoAngelica PernaMarco Alfio CutuliAlessandro MedoroLaura PietrangeloAntonio GuarnieriEmanuele FoderàDaniela PassarellaNoemi VendittiFranca VergalitoGiulio Petronio PetronioRoberto Di Marco
Published in: Pharmaceutics (2023)
(1) Background alteration of the skin microbiota, dysbiosis, causes skin barrier impairment resulting in disease development. Staphylococcus aureus , the main pathogen associated with dysbiosis, secretes several virulence factors, including α-toxin that damages tight junctions and compromises the integrity of the skin barrier. The use of members of the resident microbiota to restore the skin barrier, bacteriotherapy, represents a safe treatment for skin conditions among innovative options. The aim of this study is the evaluation of a wall fragment derived from a patented strain of Cutibacterium acnes DSM28251 (c40) alone and conjugated to a mucopolysaccharide carrier (HAc40) in counteracting S. aureus pathogenic action on two tight junction proteins (Claudin-1 and ZO-1) in an ex vivo porcine skin infection model. Methods: skin biopsies were infected with live S. aureus strains ATCC29213 and DSM20491. Tissue was pre-incubated or co-incubated with c40 and HAc40. (3) Results: c40 and HAc40 prevent and counteract Claudin-1 and Zo-1 damage (4) Conclusions: c40 and the functional ingredient HAc40 represent a potential non-pharmacological treatment of skin diseases associated with cutaneous dysbiosis of S. aureus . These findings offer numerous avenues for new research.
Keyphrases
  • soft tissue
  • staphylococcus aureus
  • wound healing
  • escherichia coli
  • oxidative stress
  • blood brain barrier
  • quality improvement
  • combination therapy
  • replacement therapy